FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science
Pan-Mass Challenge Raises Record $78 Million for Dana-Farber Cancer Institute
CD123 Targeted Therapies
Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A Brighter Future for B-ALL in Adults
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 19th Year in a Row
Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments
Showing 61 - 75 of 1027 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...69 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
